Latest
Daratumumab Not Cost-Effective for Multiple Myeloma
Ixazomib in an Oral Triplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma
Abecma Approved for Relapsed/Refractory Multiple Myeloma
Can Premedications, Infusion Rates Be Adjusted Safely With Daratumumab for Multiple Myeloma?
Rivaroxaban May Be Clinically Superior to LMWH in Patients With Cancer-Associated Thrombosis
SIRT1 Inhibitor Cambinol Has Antitumor Activity in Multiple Myeloma Cells
Pharmacy-Based VTE Screening Mitigated Risk in Myeloma Patients
BTK Inhibitors for CLL Lower Response to Some Vaccines
Pre-Transplantation MRD Status Predicts Survival in Acute Leukemia
Platelets May Be Treatment Target for Lupus
Electronic Self-Reporting Tool Improves Symptom Management During Cancer Treatment
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia
Featured Content
-
Current State and Future Directions for Treating NPM1-Mutated Acute Myeloid Leukemia
Investigators addressed challenges associated with the biology, diagnosis, and current state of treatment for patients with NPM1-mutated AML. -
NCCN Guidelines for Multiple Myeloma Updated to Include Three Selinexor Regimens
The National Comprehensive Cancer Network’s updated Clinical Practice Guidelines in Oncology for multiple myeloma newly include 3 new selinexor-containing regimens. -
Telemedicine for Hematology During COVID-19 and Beyond
The benefits of telemedicine became more evident in the context of the elevated risk of COVID-19 infection and severe symptoms among the patients served by hematology and oncology practices. -
Mild to Moderate Hemophilia: Experts Discuss Challenges and Propose Solutions
A group of US-based hemophilia experts summarized unmet needs in mild to moderate hemophilia and provided suggestions for healthcare professionals to optimally manage their patients with this challenging condition. -
American Society of Hematology Releases Updated Guidelines for Treating Newly Diagnosed AML in Older Adults
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML. -
Clinical Management of Malignant Infantile Osteopetrosis
Investigators discussed their clinical approaches to the diagnosis and management of malignant infantile osteopetrosis, as well as the management of long-term posttrasnplant complications. -
Address Possible Security Lapses as Your Practice Returns to Normal
To accommodate patients remotely during the COVID-19 pandemic, practices may have expanded personnel access to protected health information and relied on devices that might be vulnerable to cyber attacks.
-
Loading...
-
Loading...
